Quick Answer
Cytosorbents Corp reported Operating Income of -$14.75 million for fiscal year 2025.
Cytosorbents Corp Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$14.75M | +10.4% |
| 2024 | -$16.45M | +48.5% |
| 2023 | -$31.95M | -1.4% |
| 2022 | -$31.52M | -38.6% |
| 2021 | -$22.74M | -119.3% |
| 2020 | -$10.37M | +45.3% |
| 2019 | -$18.97M | -21.7% |
| 2018 | -$15.58M | -58.3% |
| 2017 | -$9.84M | +14.4% |
| 2016 | -$11.49M | -23.5% |
| 2015 | -$9.30M | -35.0% |
| 2014 | -$6.89M | -46.2% |
| 2013 | -$4.71M | -35.0% |
| 2012 | -$3.49M | +21.3% |
| 2011 | -$4.44M | -57.1% |
| 2010 | -$2.82M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.86M | +40.7% | +20.8% |
| June 30, 2025 | -$3.62M | -1.3% | +7.0% |
| March 31, 2025 | -$3.89M | +16.5% | +19.5% |
| September 30, 2024 | -$4.83M | +34.3% | -35.3% |
| June 30, 2024 | -$3.57M | +45.6% | +23.3% |
| March 31, 2024 | -$4.66M | +41.0% | +36.6% |
| September 30, 2023 | -$7.35M | +18.5% | -12.1% |
| June 30, 2023 | -$6.56M | +21.5% | +16.9% |
- Cytosorbents Corp showed an increase of +10.4% in Operating Income compared to the prior fiscal year.
- Over the 2010–2025 period, Cytosorbents Corp’s operating income has declined by 422.3% (from -$2.82 million to -$14.75 million).
- The most recent figure is from Cytosorbents Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: